Hands’ burns are a challenge for the Plastic Surgeons, since they cause functional and aesthetic problems related to invalidating scars.
Circa 80% of burned patients present hands’ wound burns which are treated, according to guidelines, with surgery procedure thus escharectomy and partial thickness dermo-epidermal graft (standard of care).
However, there are new methods such as Nexobrid and SVF (stromal vascular fraction), which represent minimal invasive modality (M.I.MO).
Nexobrid is a medicine of concentrate of proteolytic enzymes enriched in bromelain which is applied within 48 h, coating the burned region with a 1,5 mm- 3 mm layer and removed after 4 hours obtaining enzymatic selective escariolysis of the necrotic tissues.
Otherwise, SVF is obtained through physical filtration and sedimentation of lipoaspirated material set on a skin substitute (hyalomatrix) and applied on wound areas.
Our goal is to treat mid-deep hands’ burns with NEXOBRID and SVF to obtain the best functional and morphological outcomes and to compared with SOC (M.I.MO).
From January 2021 to January 2022, we have enrolled 9 patients (5 males and 4 females) with mid-deep hands’ burns, aged within 18-65 years old, with TBSA of 20%-40% and we divided them in three randomized group A, B, C each composed by 5 burned hands (same patient has been enrolled in different groups).
“A group” has been treated exclusively with Nexobrid, “B group” has been treated by combining Nexobrid with SVF (stromal vascular factor) e “C group” has been treated with surgical escharectomy and partial thickness dermo-epidermal graft.
Results have shown that in the A group’s patients healing has been achieved in a month avoiding surgery procedure with a good functional recovery.
In the B group patients have been achieved a faster healing and a best morpho-functional outcome compared to A group’s patients.
C group’s patients have obtained a complete healing in 15 days with a good functional and aesthetic outcome.
To conclude it has been observed a better aesthetic and functional result in patients treated with Nexobrid and SVF (group B) compared to those treated exclusively with Nexobrid (group A), and very similar to those treated with skin-grafts (group C).

P.128 up to date in burned hands' management using new technologies

Dear friends and colleagues,

We will be pleased to welcome you in Turin (Italy) for the 19th European Burns Association´s Congress in 2022. Italy is honored to hold the meeting of the European Burns Association for the second time, after Verona in 1995. Turin is easily reachable from everywhere in Europe, either travelling by car, train or choosing flight connections. During the meeting, held in the renewed industrial center of the main Italian historical automotive factory (i.e. Lingotto-FIAT), we will meet international burn specialists, focusing on standards of care, progresses in burn treatment, strategies to face disaster situations, with a special attention to education of younger colleagues. However, in your spare time, you might enjoy the sweet days of Italian late summer, simply wandering in the green parks and gardens along the two rivers which cross the city, or you might decide to discover the numerous art galleries, churches, palaces, libraries, walking across elegant squares and large boulevards, passing through centuries of art and history; finally, you may choose to immerse yourself in some of the most exciting museum experiences, such as the Cinema Museum and the Turin’s Egyptian museum.

Looking forward to seeing you all in Turin for the 19th European Association´s Congress in 2022!
Maurizio Stella, Congress President, Turin Burn Centre